Breast cancer is a heterogeneous disease and differs greatly among different patients
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …

During the past ten years, circulating tumour cells (CTCs) have received enormous attention
as new biomarkers and the subject of basic research. Although CTCs are already used in …

Abstract The CellSearch® system (CS) enables standardized enrichment and enumeration
of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive “liquid …

Circulating tumour cells (CTCs) are rare tumour cells found in the circulatory system of
certain cancer patients. The clinical and functional significance of CTCs is still under …

Tumor heterogeneity is a hallmark of cancer and one of the primary causes of resistance to
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …

The identification of extensive genetic heterogeneity in human breast carcinomas poses a
significant challenge for designing effective treatment regimens. Significant genomic …

Background Chemotherapy is an important component in the treatment paradigm for breast
cancers. However, the resistance of cancer cells to chemotherapeutic agents frequently …

Intermediate filament (IF) proteins make up the largest family of cytoskeletal proteins in
metazoans, and are traditionally known for their roles in fostering structural integrity in cells …

Over the past decade, technically reliable circulating tumor cell (CTC) detection methods
allowed the collection of large datasets of CTC counts in cancer patients. These data can be …

We present a critical review of microfluidic technologies and material effects on the analyses
of circulating tumour cells (CTCs) selected from the peripheral blood of cancer patients …